Table 5 Treatment-related adverse events
Adverse events | PLH (n = 84) | PL (n = 86) | HR (95%) | p-value |
|---|---|---|---|---|
Treatment-related AEs, n (%) | ||||
 Hypertension | 26 (30.9) | 25 (29.1) | 1.00 (0.42–1.79) | 0.789 |
 Fever | 20 (23.8) | 15 (17.4) | 3.00 (0.29–1.45) | 0.306 |
 Fatigue | 16 (19.0) | 12 (14.0) | 2.00 (0.44–3.79) | 0.372 |
 Decreased appetite | 14 (3.6) | 9 (10.5) | 1.00 (0.26–2.57) | 0.239 |
 Pain | 12 (14.3) | 10 (11.6) | 3.00 (0.28–5.14) | 0.607 |
 Nausea | 10 (11.9) | 8 (9.3) | 1.00 (0.11–2.02) | 0.583 |
 Diarrhea | 10 (11.9) | 6 (7.0) | 2.00 (0.43–4.22) | 0.273 |
 Cough | 7 (8.3) | 4 (4.7) | 1.00 (0.59–2.63) | 0.331 |
 Rash | 9 (10.7) | 6 (7.0) | 4.00 (0.88–6.57) | 0.392 |
 Pruritus | 5 (6.0) | 3 (3.5) | 1.00 (0.63–2.46) | 0.449 |
 Hyperthyroidism | 1 (1.2) | 1 (1.2) | 2.00 (0.47–4.02) | 0.987 |
 Hypothyroidism | 3 (3.6) | 3 (3.5) | 2.00 (0.91–3.85) | 0.977 |
 Edema peripheral | 4 (4.8) | 2 (2.3) | 1.00 (0.16–2.35) | 0.391 |
Laboratory-related AEs, n (%) | ||||
 Leukocytopenia | 12 (14.3) | 18 (20.9) | 2.00 (0.59–2.63) | 0.257 |
 Decreased PLT | 21 (25.0) | 24 (27.9) | 1.00 (0.32–3.27) | 0.668 |
 ALT or AST elevation | 47 (55.9) | 52 (60.5) | 2.00 (0.71–1.65) | 0.552 |
 TBIL elevation | 24 (28.6) | 26 (30.2) | 1.00 (0.37–2.28) | 0.813 |
 Decreased ALB | 16 (19.0) | 19 (22.1) | 1.00 (0.45–1.69) | 0.624 |